Theranostics of Metastatic Prostate Cancer Applying 64Cu/18F/68Ga PSMA PET-CT and 177Lu Radiopharmaceuticals

Curr Radiopharm. 2021;14(4):354-358. doi: 10.2174/1874471013666200908122845.

Abstract

The successful use of theranostic twins in neuroendocrine tumors (NET) is the pioneering approach to radionuclide therapy in other tumor types. 64Cu/18F PSMA for molecular imaging with PET-CT and peptide radioligand therapy (PRLT) with 177Lu labeled PSMA inhibitors are the next theranostic twins in nuclear medicine. 68Ga/ 64Cu/18F PSMA PET-CT detects metastatic prostate cancer with high diagnostic sensitivity and specificity and can be used to select patients for PRLT and evaluate therapy response. Radionuclide therapy with 177Lu-PSMA inhibitors has been shown to be effective in the treatment of metastatic CRPC.

Keywords: 64CuCl2; CRPC; NET; PET-CT; Peptide radioligand therapy; glioblastoma; melanoma.; prostate cancer.

MeSH terms

  • Copper Radioisotopes
  • Gallium Isotopes
  • Gallium Radioisotopes
  • Humans
  • Lutetium
  • Male
  • Molecular Targeted Therapy
  • Positron Emission Tomography Computed Tomography / methods*
  • Precision Medicine*
  • Prostatic Neoplasms, Castration-Resistant / diagnostic imaging*
  • Prostatic Neoplasms, Castration-Resistant / radiotherapy*
  • Radioisotopes
  • Radiopharmaceuticals / therapeutic use*
  • Sensitivity and Specificity

Substances

  • Copper Radioisotopes
  • Copper-64
  • Gallium Isotopes
  • Gallium Radioisotopes
  • Radioisotopes
  • Radiopharmaceuticals
  • gallium 68 PSMA-11
  • Lutetium
  • Lutetium-177